Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16899230 | 0.96 | ADORA2A (0.36) | ADORA2AADORA2BFKBP1A | |
| SCHEMBL18889901 | 0.84 | SMN1; SMN2 (0.40) | ADORA2AADORA2B | |
| SCHEMBL16898820 | 0.84 | SCN9A (0.32) | ADORA2AADORA2BFKBP1A | |
| SCHEMBL16898657 | 0.82 | SMN1; SMN2 (0.40) | — | |
| SCHEMBL16898670 | 0.80 | DCPS (0.33) | FKBP1A | |
| SCHEMBL16898947 | 0.80 | ADORA2A (0.38) | ADORA2AADORA2B | |
| SCHEMBL16899043 | 0.77 | KDM4E (0.33) | FKBP1A | |
| SCHEMBL360375 | 0.75 | POLB (0.48) | — | |
| SCHEMBL16898762 | 0.74 | IRAK4 (0.32) | FKBP1A | |
| SCHEMBL18889885 | 0.74 | SMN1; SMN2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152263-A1 | Substituted Indazole Compounds as IRAK4 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2017-06-01 | — | — | US | disclosed |
| EP-3157521-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2017-04-26 | — | — | EP | disclosed |
| WO-2015193846-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152263-A1 | Substituted Indazole Compounds as IRAK4 Inhibitors | IRAK4, IRAK3, IRAK2 | ADORA2A 3958/4885ADORA2B 4161/4885FKBP1A 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.